View Item 

Show simple item record

Systemic absorption of oral vancomycin in a peripheral blood stem cell transplant patient with severe graft-versus-host disease of the gastrointestinal tract

dc.contributor.authorPogue, J. M.en_US
dc.contributor.authorDePestel, Daryl D.en_US
dc.contributor.authorKaul, D. R.en_US
dc.contributor.authorKhaled, Y.en_US
dc.contributor.authorFrame, D. G.en_US
dc.date.accessioned2010-06-01T21:51:40Z
dc.date.available2010-06-01T21:51:40Z
dc.date.issued2009-10en_US
dc.identifier.citationPogue, J.M.; DePestel, D.D.; Kaul, D.R.; Khaled, Y.; Frame, D.G. (2009). "Systemic absorption of oral vancomycin in a peripheral blood stem cell transplant patient with severe graft-versus-host disease of the gastrointestinal tract." Transplant Infectious Disease 11(5): 467-470. <http://hdl.handle.net/2027.42/74898>en_US
dc.identifier.issn1398-2273en_US
dc.identifier.issn1399-3062en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/74898
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=19638004&dopt=citationen_US
dc.description.abstractOral vancomycin is often considered the drug of choice for severe Clostridium difficile- associated disease due to both its efficacy and pharmacokinetics. The potential for absorption is not well described in patients with impaired gastrointestinal (GI) mucosa. We describe a case of significant and potentially toxic absorption of oral vancomycin in a peripheral blood stem cell transplant patient with grade IV graft-versus-host disease (GVHD) of the GI tract. In patients with GI GVHD clinicians need to be aware of the potential for oral absorption and, in select cases, monitoring of levels may be appropriate.en_US
dc.format.extent96617 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishing Incen_US
dc.rights© 2009 John Wiley & Sons A/Sen_US
dc.subject.otherClostridium Difficileen_US
dc.subject.otherCDADen_US
dc.subject.otherVancomycinen_US
dc.subject.otherGVHDen_US
dc.subject.otherGraft-versus-Host Diseaseen_US
dc.subject.otherPeripheral Blood Stem Cell Transplanten_US
dc.titleSystemic absorption of oral vancomycin in a peripheral blood stem cell transplant patient with severe graft-versus-host disease of the gastrointestinal tracten_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelMedicine (General)en_US
dc.subject.hlbsecondlevelMicrobiology and Immunologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Pharmacy Services, Sinai Grace Hospital, Detroit Medical Center, Detroit, Michigan, USAen_US
dc.contributor.affiliationumDepartment of Clinical, Social, and Administrative Sciences, University of Michigan College of Pharmacy, Ann Arbor, Michigan, USAen_US
dc.contributor.affiliationumDepartment of Pharmacy Services, University of Michigan Health System, Ann Arbor, Michigan, USAen_US
dc.contributor.affiliationumDepartment of Internal Medicine, Division of Infectious Diseases, University of Michigan Medical School, Ann Arbor, Michigan, USAen_US
dc.contributor.affiliationumBlood and Marrow Transplantation Program, University of Michigan Health System, Ann Arbor, Michigan, USAen_US
dc.identifier.pmid19638004en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/74898/1/j.1399-3062.2009.00426.x.pdf
dc.identifier.doi10.1111/j.1399-3062.2009.00426.xen_US
dc.identifier.sourceTransplant Infectious Diseaseen_US
dc.identifier.citedreferenceZar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile -associated diarrhea, stratified by disease severity. Clin Infect Dis 2007; 45: 302 – 307.en_US
dc.identifier.citedreference2.  Product information. Vancocin (vancomycin hydrochloride capsules, USP pulvules). Indianapolis, IN: Eli Lilly and Company, 2000.en_US
dc.identifier.citedreferenceSpitzer PG, Eliopoulos GM. Systemic absorption of enteral vancomycin in a patient with pseudomembranous colitis. Ann Intern Med 1984; 100 ( 4 ): 533 – 534.en_US
dc.identifier.citedreferenceMatzke GR, Halstenson CE, Olson PL, Collins AJ, Abraham PA. Systemic absorption of oral vancomycin in patients with renal insufficiency and antibiotic-associated colitis. Am J Kidney Dis 1987; 5: 422 – 425.en_US
dc.identifier.citedreferenceArmstrong CJ, Wilson TS. Systemic absorption of vancomycin. J Clin Pathol 1995; 48: 689.en_US
dc.identifier.citedreferenceTedesco F, Markham R, Gurwith M, Christie D, Bartlett JG. Oral vancomycin for antibiotic-associated pseudomembranous colitis. Lancet 1978; 2: 226 – 228.en_US
dc.identifier.citedreferenceDudley MN, Quintiliani R, Nightingale, Gontarz N. Absorption of vancomycin. Ann Intern Med 1984; 101: 144.en_US
dc.identifier.citedreferenceAradhyula S, Manian FA, Hafidh SA, Bhutto SS, Alpert MA. Significant absorption of oral vancomycin in a patient with Clostridium difficile colitis and normal renal function. South Med J 2005; 99 ( 5 ): 518 – 520.en_US
dc.identifier.citedreferenceFekely R, Silva J, Kauffman, Buggy B, Deery HG. Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. Am J Med 1989; 86 ( 1 ): 15 – 19.en_US
dc.identifier.citedreferenceOsawa R, Kaka A. Maculopapular rash induced by oral vancomycin. Clin Infect Dis 2008; 47: 880 – 881.en_US
dc.identifier.citedreferenceBailey P, Gray H. An elderly woman with “Red Man Syndrome” in association with oral vancomycin therapy: a case report. Cases J 2008; 1: 111.en_US
dc.identifier.citedreferenceLeisenring WM, Martin PJ, Petersdorf EW, et al. An acute graft-versus-host disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimens. Blood 2006; 108 ( 2 ): 749 – 755.en_US
dc.identifier.citedreferenceKelly C, LaMont JT. Clostridium difficile – more difficult than ever. N Engl J Med 2008; 359: 1932 – 1940.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1399-3062.2009.00426.x.pdf
Size:
94.35KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.